Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
5.45
+0.08 (1.42%)
Aug 13, 2025, 4:00 PM - Market closed

Eupraxia Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Selling, General & Admin
12.1610.927.483.996.481
Upgrade
Research & Development
16.9816.0820.3613.637.580.67
Upgrade
Operating Expenses
29.142727.8517.6214.151.76
Upgrade
Operating Income
-29.14-27-27.85-17.62-14.15-1.76
Upgrade
Interest Expense
-0.36-0.96-1.17-0.98-0.97-1.48
Upgrade
Interest & Investment Income
1.091.160.860.430.050
Upgrade
Currency Exchange Gain (Loss)
-0.62-0.160.070.240.160.1
Upgrade
Other Non Operating Income (Expenses)
-1.2-0.84-1.06-4.740.1
Upgrade
EBT Excluding Unusual Items
-29.03-25.76-28.92-18.98-19.65-3.04
Upgrade
Gain (Loss) on Sale of Assets
0.010.02-0-0.01--0.1
Upgrade
Other Unusual Items
----0.42-
Upgrade
Pretax Income
-29.03-25.74-28.93-18.99-19.23-3.15
Upgrade
Income Tax Expense
0.0100.04---
Upgrade
Earnings From Continuing Operations
-29.04-25.74-28.97-18.99-19.23-3.15
Upgrade
Minority Interest in Earnings
0.080.240.750.50.30.01
Upgrade
Net Income
-28.96-25.5-28.22-18.49-18.93-3.14
Upgrade
Preferred Dividends & Other Adjustments
0.430.43----
Upgrade
Net Income to Common
-29.38-25.93-28.22-18.49-18.93-3.14
Upgrade
Shares Outstanding (Basic)
36342419126
Upgrade
Shares Outstanding (Diluted)
36342419126
Upgrade
Shares Change (YoY)
21.81%40.52%25.21%55.45%102.75%0.01%
Upgrade
EPS (Basic)
-0.82-0.76-1.17-0.96-1.53-0.51
Upgrade
EPS (Diluted)
-0.86-0.76-1.17-0.96-1.53-0.51
Upgrade
Free Cash Flow
-30.89-30.1-20.82-14.63-12.06-0.32
Upgrade
Free Cash Flow Per Share
-0.86-0.89-0.86-0.76-0.97-0.05
Upgrade
EBITDA
-28.98-26.89-27.73-17.51-14.11-1.73
Upgrade
D&A For EBITDA
0.170.110.110.110.040.03
Upgrade
EBIT
-29.14-27-27.85-17.62-14.15-1.76
Upgrade
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q